Company Analysis
Sign in

Neuraxis, Inc. (NRXS)

NYSE: NRXS · Electromedical & Electrotherapeutic Apparatus · Carmel, IN · filing with the SEC since 2022
Full chart Alerts Compare
Grade4.5
◀ Past 3.2● Present 3.6▶ Future 6.9
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Neuraxis, Inc.

Nine metrics read from its own filings, by tense
Headline grade
4.5/10
◀ Past3.230% of the headline
● Present3.640% of the headline
▶ Future6.930% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.2/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.2/10

Has it survived what it has been through?

4 warning events since 2022; the latest 2024-05-15.

weight 33% of this tense · 22nd percentile among 27 sector filers · read for itself

From the record

Neuraxis, Inc.'s filings since 2022 show 4 warning events of 2 kinds: a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-04-09); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2024-05-15) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.9/10

What has it actually done, year after year?

+10% a year over 4 filed years; profitable in 0 of 4.

weight 45% of this tense · 39th percentile among 25 sector filers · read for its customers

From the record

Neuraxis, Inc.'s 4 filed years say what it did: revenue went from $3 million in fiscal 2022 to $4 million in fiscal 2025, up 10% a year; it rose in 2 of 3 years; the deepest fall was 8% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span10.0%bottom 41% of its family
  • the share of years revenue rosebottom 28% of its family
  • the share of filed years with a profitbottom 29% of its family
  • the deepest fall from a revenue peak8.4%top 42% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
3.1/10

How has it treated the people who own it?

SI estimate 3.1/10, confidence 35 of 100 (one part).

weight 22% of this tense · 31st percentile among 27 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 31% of 27 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 27 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuraxis, Inc.'s shareholder treatment is put at 3.1 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 31% of 27 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

3.6/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
4.4/10

Is it financially healthy right now?

ROE -229%: lost 229¢ per shareholder dollar. Leverage 47%: owes 47¢ per asset dollar.

weight 45% of this tense · 44th percentile among 27 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Neuraxis, Inc. lost about 229 cents for every dollar of shareholders' money, and gross profitability: its products earned about 47 cents per dollar of everything the company owns. Leverage: it owed about 47 cents per dollar of assets, and net share issuance: its share count grew 31.3% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 46% of its family
  • return on equitybottom 18% of its family
  • gross profit against assetstop 24% of its family
  • the share count against the year beforebottom 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
2.9/10

How strong is its position in its industry?

bottom 29% of 24 in its family; net margin -218.5%.

weight 33% of this tense · 29th percentile among 24 sector filers · read for its customers

From the record

Neuraxis, Inc.'s standing among 24 graded names in its industry family: revenue of $4 million in fiscal 2025 ranks in the bottom 19% by size; a net margin of -218.5% ranks in the bottom 23%; revenue growth of 10% a year over the last 3 filed years ranks in the bottom 46% (its annual reports).

What it rests on

  • revenue against the family$3.6Mbottom 19% of its family
  • net margin-218.5%bottom 23% of its family
  • three-year revenue growth10.0%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
3.0/10

What are the people in charge doing?

SI estimate 3.0/10, confidence 35 of 100 (one part).

weight 22% of this tense · 30th percentile among 25 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 30% of 25 in its family; the record of its people begins on 2023-08-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.3 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2023-08-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.3 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 25 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Neuraxis, Inc.'s leadership is put at 3.0 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the bottom 30% of 25 in its family; the record of its people begins on 2023-08-08 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.3 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.9/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.4/10

How much room does it have to grow?

top 36% of 23 in its family for room to expand.

weight 45% of this tense · 64th percentile among 23 sector filers · read for itself

From the record

Neuraxis, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $5 million against no long-term debt tagged leaves 77.5% of its assets as net cash, top 2% of its family; cash from operations less capital spending is -181.1% of revenue (bottom 15%); a gross margin of 84.2% (top 11%); research spending of 13.8% of revenue (top 48%) (its annual report).

What it rests on

  • cash less debt against assets77.5%top 2% of its family
  • cash from operations less capital spending against revenue-181.1%bottom 15% of its family
  • gross margin84.2%top 11% of its family
  • research spending against revenue13.8%top 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
7.3/10

What could actually drive growth from here?

top 27% of 25 in its family for growth drivers.

weight 33% of this tense · 73rd percentile among 25 sector filers · read for its customers

From the record

Neuraxis, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 10% a year over the last three filed years against 10% over all 4, speeding up (top 46% of its family); the newest year grew 32.9% (top 24%); research spending grew 29.8% a year (top 22%); capital spending grew 181.9% a year (top 15%) (its annual reports). Neuraxis, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 46% of its family
  • the newest year's revenue growth32.9%top 24% of its family
  • three-year growth of research spending29.8%top 22% of its family
  • three-year growth of capital spending181.9%top 15% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
7.3/10

Did its newest year beat what its own record pointed to?

top 27% of 20 in its family for expectations against reality.

weight 22% of this tense · 73rd percentile among 20 sector filers · read for its shareholders

From the record

Neuraxis, Inc.'s newest year against its own record: revenue of $4 million in fiscal 2025 came in 32.9% above the $3 million its prior three years' pace pointed to (top 17% of its family); net income of $8 million against a prior three-year average of $9 million (bottom 48%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 12%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace32.9%top 17% of its family
  • net income against the prior three years' average+15%bottom 48% of its family
  • net margin against its prior averageup more than 100 pointstop 12% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton NRXS · research, not advice